Primary progressive multiple sclerosis - Why we are failing

Benjamin M. Segal; Olaf Stüve

doi:10.1016/S0140-6736(16)00158-6

Primary progressive multiple sclerosis - Why we are failing

Benjamin M. Segal, Olaf Stüve

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1032-1034
Number of pages	3
Journal	The Lancet
Volume	387
Issue number	10023
DOIs	https://doi.org/10.1016/S0140-6736(16)00158-6
State	Published - Mar 12 2016

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(16)00158-6

Cite this

@article{587e4a0eeb204707959c6a0108d433a7,

title = "Primary progressive multiple sclerosis - Why we are failing",

author = "Segal, {Benjamin M.} and Olaf St{\"u}ve",

note = "Funding Information: BMS reports personal fees from Vitae Pharmaceuticals, Novartis, Best Doctors Inc, Bristol-Myers Squibb, and grants from Biogen Idec. OS reports grants from Teva Pharamceuticas, Opexa Therapeutics, and Medscape, personal fees from Genetech, Sanofi Aventis, Huron Life Sciences, Navigant Consulting, and travel expenses from Pfizer, Sanofi-Aventis, JAMA Neurology, Multiple Sclerosis Journal, Therpeutic Advances in Neurological Disorders , Pfizer, and Novartis. ",

year = "2016",

month = mar,

day = "12",

doi = "10.1016/S0140-6736(16)00158-6",

language = "English (US)",

volume = "387",

pages = "1032--1034",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10023",

}

TY - JOUR

T1 - Primary progressive multiple sclerosis - Why we are failing

AU - Segal, Benjamin M.

AU - Stüve, Olaf

N1 - Funding Information: BMS reports personal fees from Vitae Pharmaceuticals, Novartis, Best Doctors Inc, Bristol-Myers Squibb, and grants from Biogen Idec. OS reports grants from Teva Pharamceuticas, Opexa Therapeutics, and Medscape, personal fees from Genetech, Sanofi Aventis, Huron Life Sciences, Navigant Consulting, and travel expenses from Pfizer, Sanofi-Aventis, JAMA Neurology, Multiple Sclerosis Journal, Therpeutic Advances in Neurological Disorders , Pfizer, and Novartis.

PY - 2016/3/12

Y1 - 2016/3/12

UR - http://www.scopus.com/inward/record.url?scp=84961285268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961285268&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)00158-6

DO - 10.1016/S0140-6736(16)00158-6

M3 - Comment/debate

C2 - 26827076

AN - SCOPUS:84961285268

SN - 0140-6736

VL - 387

SP - 1032

EP - 1034

JO - The Lancet

JF - The Lancet

IS - 10023

ER -

Primary progressive multiple sclerosis - Why we are failing

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this